Latest filing published 05 May 2026 for AMGEN INC, €740k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Robert A. Bradway (chief executive) discloses dealings in Amgen Inc to SEC (Form 4). The record holds 33 filings, for trades running from 28 January 2016 to 2 May 2026.
The filings describe grants, exercises and other transfers rather than trades on the open market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
The newest entry dates from 5 May 2026: a share grant of €740k, in Amgen Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 33 declarations